Header Logo

Connection

RAJENDER APARASU to Retrospective Studies

Back to Details
This is a "connection" page, showing publications RAJENDER APARASU has written about Retrospective Studies.
RAJENDER APARASU
Connection Strength
2.187
Retrospective Studies
  1. Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
    View in: PubMed
    Score: 0.067
  2. Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
    View in: PubMed
    Score: 0.067
  3. Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
    View in: PubMed
    Score: 0.066
  4. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539.
    View in: PubMed
    Score: 0.064
  5. Cumulative Anticholinergic Burden and its Predictors among Older Adults with Alzheimer's Disease Initiating Cholinesterase Inhibitors. Drugs Aging. 2024 Apr; 41(4):339-355.
    View in: PubMed
    Score: 0.064
  6. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study. Clin Ther. 2023 09; 45(9):e177-e186.
    View in: PubMed
    Score: 0.061
  7. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023 06; 43(6):473-484.
    View in: PubMed
    Score: 0.060
  8. Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. Drugs Aging. 2022 06; 39(6):453-465.
    View in: PubMed
    Score: 0.056
  9. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
    View in: PubMed
    Score: 0.055
  10. Risk of overactive bladder associated with cholinesterase inhibitors in dementia. J Am Geriatr Soc. 2022 03; 70(3):820-830.
    View in: PubMed
    Score: 0.054
  11. Prescribing of disease modifying agents in older adults with multiple sclerosis. Mult Scler Relat Disord. 2022 Jan; 57:103308.
    View in: PubMed
    Score: 0.054
  12. Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia. Drugs Aging. 2021 07; 38(7):593-602.
    View in: PubMed
    Score: 0.052
  13. Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study. Drugs Aging. 2021 06; 38(6):493-502.
    View in: PubMed
    Score: 0.052
  14. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021 05; 41(5):440-450.
    View in: PubMed
    Score: 0.052
  15. Prevalence and Factors Associated with Cumulative Anticholinergic Burden Among Older Long-Stay Nursing Home Residents with Overactive Bladder. Drugs Aging. 2021 04; 38(4):311-326.
    View in: PubMed
    Score: 0.052
  16. Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder. Int J Geriatr Psychiatry. 2021 05; 36(5):684-696.
    View in: PubMed
    Score: 0.051
  17. Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries. J Am Med Dir Assoc. 2021 06; 22(6):1300-1306.
    View in: PubMed
    Score: 0.050
  18. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries. Adv Ther. 2020 08; 37(8):3584-3605.
    View in: PubMed
    Score: 0.049
  19. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
    View in: PubMed
    Score: 0.049
  20. Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
    View in: PubMed
    Score: 0.049
  21. Risk of Mortality Associated With Atypical Antipsychotic use: A National Cohort Study of Older Adults With Depression and Parkinson's Disease. Am J Geriatr Psychiatry. 2020 10; 28(10):1079-1088.
    View in: PubMed
    Score: 0.048
  22. Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study. J Gen Intern Med. 2020 07; 35(7):2084-2093.
    View in: PubMed
    Score: 0.048
  23. Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine. Pharmacotherapy. 2017 03; 37(3):287-296.
    View in: PubMed
    Score: 0.039
  24. Discharge medication complexity and 30-day heart failure readmissions. Res Social Adm Pharm. 2017 Jul - Aug; 13(4):857-863.
    View in: PubMed
    Score: 0.038
  25. Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder. Drugs Aging. 2016 10; 33(10):755-763.
    View in: PubMed
    Score: 0.038
  26. Comparative risk of hip fractures in elderly nursing home patients with depression using paroxetine and other selective serotonin reuptake inhibitors. J Comp Eff Res. 2016 08; 5(5):461-73.
    View in: PubMed
    Score: 0.037
  27. Comparative Effectiveness of Second-Generation Antidepressants in Reducing the Risk of Dementia in Elderly Nursing Home Residents with Depression. Pharmacotherapy. 2016 Jan; 36(1):38-48.
    View in: PubMed
    Score: 0.036
  28. Comparative Cognitive Profile of Second-Generation Antidepressants in Elderly Nursing Home Residents With Depression. Ann Pharmacother. 2016 Feb; 50(2):96-105.
    View in: PubMed
    Score: 0.036
  29. Cardiovascular Safety of Concomitant Use of Atypical Antipsychotics and Long-Acting Stimulants in Children and Adolescents With ADHD. J Atten Disord. 2019 01; 23(2):163-172.
    View in: PubMed
    Score: 0.036
  30. Quality of life of patients with Parkinson's disease and neurodegenerative dementia: A nationally representative study. Res Social Adm Pharm. 2016 Jul-Aug; 12(4):604-13.
    View in: PubMed
    Score: 0.035
  31. Risk of Dementia Among Elderly Nursing Home Patients Using Paroxetine and Other Selective Serotonin Reuptake Inhibitors. Psychiatr Serv. 2015 Dec 01; 66(12):1333-40.
    View in: PubMed
    Score: 0.035
  32. Predictors of concomitant use of antipsychotics and stimulants and its impact on stimulant persistence in pediatric attention deficit hyperactivity disorder. J Manag Care Spec Pharm. 2015 Jun; 21(6):486-98.
    View in: PubMed
    Score: 0.035
  33. Potentially inappropriate anticholinergic medication use in community-dwelling older adults: a national cross-sectional study. Drugs Aging. 2015 May; 32(5):379-89.
    View in: PubMed
    Score: 0.034
  34. Anticholinergic drugs and health-related quality of life in older adults with dementia. J Am Pharm Assoc (2003). 2015 May-Jun; 55(3):282-7.
    View in: PubMed
    Score: 0.034
  35. Concurrent use of stimulants and second-generation antipsychotics among children with ADHD enrolled in Medicaid. Psychiatr Serv. 2015 Apr 01; 66(4):404-10.
    View in: PubMed
    Score: 0.034
  36. Risk of hospitalization and use of first- versus second-generation antipsychotics among nursing home residents. Psychiatr Serv. 2014 Jun 01; 65(6):781-8.
    View in: PubMed
    Score: 0.032
  37. Risk of pneumonia in elderly nursing home residents using typical versus atypical antipsychotics. Ann Pharmacother. 2013 Apr; 47(4):464-74.
    View in: PubMed
    Score: 0.030
  38. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012 Apr; 22(2):139-48.
    View in: PubMed
    Score: 0.028
  39. Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study. Am J Geriatr Pharmacother. 2012 Apr; 10(2):83-94.
    View in: PubMed
    Score: 0.028
  40. Risk of serious cardiac events in older adults using antipsychotic agents. Am J Geriatr Pharmacother. 2011 Apr; 9(2):120-32.
    View in: PubMed
    Score: 0.026
  41. Risk of falls and fractures in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. Drugs Aging. 2010 Oct 01; 27(10):815-29.
    View in: PubMed
    Score: 0.025
  42. Extent of functional impairment in children and adolescents with depression. Curr Med Res Opin. 2010 Sep; 26(9):2057-64.
    View in: PubMed
    Score: 0.025
  43. Risk of cerebrovascular adverse events in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. J Clin Psychiatry. 2010 Jun; 71(6):689-98.
    View in: PubMed
    Score: 0.025
  44. Unmet prescription medication need in U.S. children. J Am Pharm Assoc (2003). 2009 Nov-Dec; 49(6):769-76.
    View in: PubMed
    Score: 0.024
  45. Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. Am J Geriatr Pharmacother. 2008 Oct; 6(4):198-204.
    View in: PubMed
    Score: 0.022
  46. Factors associated with the use of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease: A SEER-Medicare study. J Geriatr Oncol. 2024 11; 15(8):102071.
    View in: PubMed
    Score: 0.017
  47. Pain-related hospitalization and emergency room visit following initial analgesic prescription after outpatient surgery. Pharmacoepidemiol Drug Saf. 2024 02; 33(2):e5759.
    View in: PubMed
    Score: 0.016
  48. Adherence to Recommended Metabolic Monitoring of Children and Adolescents Taking Second-Generation Antipsychotics. Psychiatr Serv. 2024 Apr 01; 75(4):342-348.
    View in: PubMed
    Score: 0.015
  49. Impact of the AACAP practice parameters on the metabolic adverse event monitoring for second-generation antipsychotics (SGAs) in children and adolescents. J Psychiatr Res. 2023 09; 165:170-173.
    View in: PubMed
    Score: 0.015
  50. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc. 2003 May; 51(5):671-7.
    View in: PubMed
    Score: 0.015
  51. Impact of geographic access to primary care providers on pediatric behavioral health screening. Prev Med. 2021 12; 153:106856.
    View in: PubMed
    Score: 0.013
  52. Racial/ethnic differences in treatment quality among youth with primary care provider-initiated versus mental health specialist-initiated care for major depressive disorders. Child Adolesc Ment Health. 2020 02; 25(1):28-35.
    View in: PubMed
    Score: 0.012
  53. Reversibility of psychotropic medication induced weight gain among children and adolescents with bipolar disorders. Psychiatry Res. 2019 06; 276:151-159.
    View in: PubMed
    Score: 0.011
  54. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019 04 01; 125(7):1155-1162.
    View in: PubMed
    Score: 0.011
  55. Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders. J Manag Care Spec Pharm. 2019 Jan; 25(1):29-38.
    View in: PubMed
    Score: 0.011
  56. Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect. 2018 07; 146(9):1101-1105.
    View in: PubMed
    Score: 0.011
  57. Effect of Psychopharmacotherapy on Body Mass Index Among Children and Adolescents with Bipolar Disorders. J Child Adolesc Psychopharmacol. 2017 May; 27(4):349-358.
    View in: PubMed
    Score: 0.010
  58. Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure. Am J Alzheimers Dis Other Demen. 2016 08; 31(5):395-404.
    View in: PubMed
    Score: 0.009
  59. Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study. Drugs Aging. 2015 Sep; 32(9):743-54.
    View in: PubMed
    Score: 0.009
  60. Risk of manic switch associated with antidepressant therapy in pediatric bipolar depression. J Child Adolesc Psychopharmacol. 2014 Dec; 24(10):551-61.
    View in: PubMed
    Score: 0.008
  61. Comparative effectiveness of monotherapy with mood stabilizers versus second generation (atypical) antipsychotics for the treatment of bipolar disorder in children and adolescents. Pharmacoepidemiol Drug Saf. 2014 Mar; 23(3):299-308.
    View in: PubMed
    Score: 0.008
  62. Application of the nonlinear Blinder-Oaxaca decomposition to study racial/ethnic disparities in antiobesity medication use in the United States. Res Social Adm Pharm. 2013 Jan-Feb; 9(1):13-26.
    View in: PubMed
    Score: 0.007
  63. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimers Dement. 2012 Sep; 8(5):437-44.
    View in: PubMed
    Score: 0.007
  64. Comparative effectiveness of different angiotensin-converting enzyme inhibitors on the risk of hospitalization in patients with heart failure. J Comp Eff Res. 2012 Mar; 1(2):195-206.
    View in: PubMed
    Score: 0.007
  65. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiol Drug Saf. 2012 Mar; 21(3):233-40.
    View in: PubMed
    Score: 0.007
  66. Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: a multiple-propensity analysis. Res Social Adm Pharm. 2012 Mar-Apr; 8(2):145-56.
    View in: PubMed
    Score: 0.007
  67. Risk factors for dementia in patients over 65 with diabetes. Int J Geriatr Psychiatry. 2011 Jul; 26(7):749-57.
    View in: PubMed
    Score: 0.006
  68. Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature. Pharmacotherapy. 2006 Sep; 26(9):1307-13.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.